Moreover, PD-L1 immunohistochemistry can predict the pathological responses to PD-1 inhibitors and neoadjuvant chemotherapy which is similar to the conclusions obtained from KEYNOTE-048 and CheckMate-141 clinical trials in recurrent and metastatic HNSCC (6, 7). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.